Impact of Thoracic Radiotherapy on First-Line Treatment Outcomes in ES-SCLC Patients

被引：0
|
作者：
Xiaoli, M. [1 ]
Yan, L. [2 ]
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[2] Lung Canc Ctr, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Thoracic Radiotherapy; first-line immunotherapy and chemotherapy; extensive-stage small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.13D.08
引用
收藏
页码：S678 / S678
页数：1
相关论文
共 50 条
  • [41] First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.
    Chen, Yuanbin
    Paz-Ares, Luis G.
    Dvorkin, Mikhail
    Trukhin, Dmytro
    Reinmuth, Niels
    Chiara Garassino, Marina
    Statsenko, Galina
    Voitko, Oleksandr
    Hochmair, Maximilian
    Ozguroglu, Mustafa
    Verderame, Francesco
    Havel, Libor
    Losonczy, Gyorgy
    Conev, Nikolay
    Hotta, Katsuyuki
    Ji, Jun Ho
    Broadhurst, Helen
    Byrne, Natalie
    Thiyagarajah, Piruntha
    Wade Goldman, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Sintilimab in Combination With Carboplatin/Cisplatin and Etoposide in the Treatment of Patients with Previously Untreated ES-SCLC
    Xie, M.
    Zhao, J.
    Su, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S375 - S375
  • [43] Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial.
    Zhou, Lin
    Sun, Jianguo
    Xie, Conghua
    Gong, Youling
    Huang, Meijuan
    Yuan, Zhiyong
    Wu, Lin
    Wang, Hui
    Bi, Nan
    Xu Yaping
    Zhu, Jiang
    Zhang, Yan
    Fan, Min
    Zou, Bingwen
    Yu, Min
    Na, Feifei
    Xiu, Weigang
    Zhang, Xuanwei
    Xue, Jianxin
    Lu, You
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] A phase II trial of carboplatin and irinotecan as first-line therapy for extensive stage small cell lung cancer (ES-SCLC): Preliminary results
    Laskin, J
    Shirley, B
    Dobbs, T
    Bi, J
    Carbone, D
    Johnson, D
    Sandler, A
    LUNG CANCER, 2005, 49 : S323 - S323
  • [45] Durvalumab ± tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.
    Paz-Ares, Luis G.
    Dvorkin, Mikhail
    Chen, Yuanbin
    Reinmuth, Niels
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian
    Ozguroglu, Mustafa
    Ji, Jun Ho
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Armstrong, Jon
    Byrne, Natalie
    Jiang, Haiyi
    Goldman, Jonathan Wade
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Outcomes of Chemoimmunotherapy in Patients with ES-SCLC According to Liver Metastasis: A Multicenter Prospective Cohort Study
    Harutani, Y.
    Fujimoto, D.
    Tamiya, M.
    Matsumoto, H.
    Kijima, T.
    Sato, Y.
    Sugisaka, J.
    Taniguchi, Y.
    Hara, S.
    Yokoyama, T.
    Hino, A.
    Uchida, J.
    Furuya, N.
    Daga, H.
    Ikeda, H.
    Hiraoka, R.
    Suzuki, H.
    Koh, Y.
    Yamamoto, N.
    Akamatsu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S371 - S372
  • [47] Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy
    Dragnev, K. H.
    Owonikoko, T. K.
    Csoszi, T.
    Maglakelidze, M.
    Beck, J. T.
    Gomez, M. Domine
    Lowczak, A.
    Fulop, A.
    Hoyer, R. J.
    Hanna, W.
    Lowry, P.
    Aljumaily, R.
    Chiu, V. K.
    Bulat, I.
    Yang, Z.
    Roberts, P. J.
    Antal, J. M.
    Malik, R. K.
    Morris, S. R.
    Weiss, J. M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [48] Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy
    Sorrentino, J. A.
    Lai, A.
    Weiss, J. M.
    Dragnev, K. H.
    Owonikoko, T. K.
    Adler, S.
    Antal, J. M.
    Malik, R. K.
    Roberts, P. J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Outcomes of ES-SCLC Patients Treated with Platinum Doublet and Immunotherapy: A Western Australia Retrospective Review
    Lee, J. W. H.
    Lam, W. -S.
    Bowyer, S.
    Oh, L.
    Khoo, T.
    Lee, H.
    Warburton, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S693 - S694
  • [50] Durvalumab ± tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study
    Grohe, C.
    Paz-Ares, L. G.
    Dvorkin, M.
    Chen, Y.
    Hotta, K.
    Trukhin, D.
    Statsenko, G.
    Hochmair, M. J.
    Ozguroglu, M.
    Ji, J. H.
    Voitko, O.
    Poltoratskiy, A.
    Verderame, F.
    Havel, L.
    Bondarenko, I.
    Armstrong, J.
    Byrne, N.
    Jiang, H.
    Goldman, J. W.
    Reinmuth, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 149 - 149
12345